The drug of the therapeutic system is Parkinson's disease.

摘要

The present invention provides an area of 10 to 40 square centimeters using a silicon-based transdermal treatment system and a content of 0.1 to 315 mg/cm 2 rho_gamma. _as an active component of the drug, on Friday, an improvement was achieved in Parkinson's disease, compared with a sham treatment, case a Human and Parkinson's diseaseUniform Parkinson's Disease Rating Scale (UPDRS) according to the scale of assessment, Parkinson's Disease Rating Scale, Part 2 and Part 3, at one IP at two or more times after administration At least 7 weeks.